Narrative Update on Bio-Techne
Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value.
What’s in the News
- Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union. This allows hospitals and labs to use it as a validated platform for in-house test development, clinical trials, and other translational activities (Product-Related Announcement).
- Company launched the Cultrex Synthetic Hydrogel, a fully defined extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research. It supports applications such as drug screening, toxicology, and personalized medicine (Product-Related Announcement).
- New Simple Plex Ultra-Sensitive Assays were introduced on the Ella platform to quantify low-abundance neurodegenerative disease biomarkers like NFL, GFAP, pTau 217, and Amyloid b (aa1-42). These assays have run times under three hours and are intended for research use only (Product-Related Announcement).
- Lunaphore, a Bio-Techne spatial biology brand, entered a collaboration with the Wyss Center for Bio and Neuroengineering in Geneva to develop automated workflows for simultaneous RNA and protein detection in 3D specimens. The collaboration aims to extend multiomic spatial biology from 2D into 3D samples (Strategic Alliances).
- Expanded launch and first shipment of the next-generation Leo System, powered by Simple Western Technology, added dual-channel fluorescence to chemiluminescence. This enables higher data throughput, more multiplexing options, and the ability to run up to 100 capillaries within three hours (Product-Related Announcement).
Valuation Changes
- Fair Value: updated assessment increased from $70.00 to $75.25, indicating a modest upward adjustment in the analyst fair value estimate.
- Discount Rate: revised slightly from 7.82% to 7.83%, reflecting a very small change in the rate used to discount future cash flows.
- Revenue Growth: updated assumption moved from 5.94% to 6.81%, pointing to a slightly higher expected top line growth profile in the model.
- Net Profit Margin: refined from 18.94% to 18.96%, a very small change in expected profitability levels.
- Future P/E: forward P/E assumption adjusted from 47.73x to 52.08x, indicating a somewhat higher multiple applied to future earnings in the updated valuation.
Have other thoughts on Bio-Techne?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.